Receptor Pharmacology Unit, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):627-35. doi: 10.2174/187152710793361504.
Our understanding of the complex signaling neurophysiology of the central nervous system has facilitated the exploration of potential novel receptor-ligand system targets for disorders of this most complex organ. In recent years, many relatively neglected receptor-ligand systems have been re-evaluated with respect to their ability to potently modulate discrete tracts in the central nervous system. One such system is the tachykinin (previously neurokinin) system. The multiple heptahelical G protein-coupled receptors and neuropeptide ligands that comprise this system may be significantly involved in more central nervous systems actions than previously thought, including sleep disorders, amyotrophic lateral sclerosis, Alzheimer's disease and Machado-Joseph disease. The development of our understanding of the role of the tachykinin receptor-ligand system in higher order central functions is likely to allow the creation of more specific and selective tachykinin-related neurotherapeutics.
我们对中枢神经系统复杂信号神经生理学的理解促进了对该最复杂器官疾病的潜在新型受体-配体系统靶标的探索。近年来,许多相对被忽视的受体-配体系统已经重新评估了其在调节中枢神经系统离散途径方面的强大能力。这样的系统之一是速激肽(以前称为神经激肽)系统。该系统包含的多种七螺旋 G 蛋白偶联受体和神经肽配体可能比以前认为的更广泛地参与中枢神经系统的作用,包括睡眠障碍、肌萎缩侧索硬化症、阿尔茨海默病和 Machado-Joseph 病。我们对速激肽受体-配体系统在高级中枢功能中的作用的理解的发展,可能会允许创造更特异和选择性的速激肽相关神经治疗。